• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.骨髓增殖性疾病中通过血流介导的血管舒张评估内皮功能障碍
Clin Appl Thromb Hemost. 2018 Oct;24(7):1102-1108. doi: 10.1177/1076029618766260. Epub 2018 Apr 22.
2
Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders.费城染色体阴性骨髓增殖性疾病患者的隐匿性脑梗死
J Clin Med. 2021 Dec 21;11(1):13. doi: 10.3390/jcm11010013.
3
[Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].[BCR/ABL 阴性骨髓增殖性疾病的诊断与治疗——CZEMP 建议的原则与依据]
Vnitr Lek. 2011 Feb;57(2):189-213.
4
The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.2001年世界卫生组织以及更新后的欧洲关于费城染色体阴性慢性骨髓增殖性疾病的诊断、分类及分期的临床和病理标准。
Semin Thromb Hemost. 2006 Jun;32(4 Pt 2):307-40. doi: 10.1055/s-2006-942754.
5
Influence of Blood Count, Cardiovascular Risks, Inherited Thrombophilia, and JAK2 V617F Burden Allele on Type of Thrombosis in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms.血细胞计数、心血管风险、遗传性血栓形成倾向、JAK2 V617F 负荷等位基因对费城染色体阴性骨髓增殖性肿瘤患者血栓类型的影响。
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):53-63. doi: 10.1016/j.clml.2018.08.020. Epub 2018 Sep 10.
6
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.费城染色体阴性骨髓增殖性肿瘤的临床表现及并发症危险因素
Asian Pac J Cancer Prev. 2015;16(12):5013-8. doi: 10.7314/apjcp.2015.16.12.5013.
7
Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis.骨髓增殖性疾病（原发性血小板增多症、真性红细胞增多症、原发性巨核细胞粒细胞化生及骨髓纤维化）的诊断、发病机制与治疗
Neth J Med. 1999 Feb;54(2):46-62. doi: 10.1016/s0300-2977(98)00143-0.
8
Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.JAK2 V617F 阳性骨髓增殖性疾病中的表型变异性：祖细胞和中性粒细胞等位基因负荷的作用。
Exp Hematol. 2008 Nov;36(11):1480-6. doi: 10.1016/j.exphem.2008.05.006. Epub 2008 Aug 23.
9
Chronic myeloproliferative diseases.慢性骨髓增殖性疾病
Handb Clin Neurol. 2014;120:1073-81. doi: 10.1016/B978-0-7020-4087-0.00072-3.
10
WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.世界卫生组织（WHO）骨髓特征及欧洲临床、分子和病理（ECMP）诊断骨髓增殖性疾病标准。
Leuk Res. 2007 Aug;31(8):1031-8. doi: 10.1016/j.leukres.2007.01.021. Epub 2007 Mar 23.

引用本文的文献

1
Primary myelofibrosis with thrombophilia as first symptom combined with thalassemia and Gilbert syndrome: A case report.以血栓形成倾向为首发症状并合并地中海贫血和吉尔伯特综合征的原发性骨髓纤维化：一例报告
World J Clin Cases. 2022 May 6;10(13):4161-4170. doi: 10.12998/wjcc.v10.i13.4161.
2
Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders.费城染色体阴性骨髓增殖性疾病患者的隐匿性脑梗死
J Clin Med. 2021 Dec 21;11(1):13. doi: 10.3390/jcm11010013.
3
Comparative Mutational Profiling of Hematopoietic Progenitor Cells and Circulating Endothelial Cells (CECs) in Patients with Primary Myelofibrosis.原发性骨髓纤维化患者造血祖细胞与循环内皮细胞的比较突变分析。
Cells. 2021 Oct 15;10(10):2764. doi: 10.3390/cells10102764.
4
COVID 19 disease independently predicted endothelial dysfunction measured by flow-mediated dilatation.COVID-19 疾病独立预测了通过血流介导扩张测量的内皮功能障碍。
Int J Cardiovasc Imaging. 2022 Jan;38(1):25-32. doi: 10.1007/s10554-021-02356-3. Epub 2021 Jul 20.
5
Two Cases of Severe Hypertension in JAK2 Mutation-Positive Myeloproliferative Neoplasms.JAK2 突变阳性骨髓增殖性肿瘤伴严重高血压两例
Case Rep Vasc Med. 2020 Nov 9;2020:8887423. doi: 10.1155/2020/8887423. eCollection 2020.
6
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper.解决和提出骨髓增殖性肿瘤相关血栓形成管理中未满足的临床需求的方案：基于共识的立场文件。
Blood Cancer J. 2019 Aug 8;9(8):61. doi: 10.1038/s41408-019-0225-5.

本文引用的文献

1
Cardiovascular Manifestations of Myeloproliferative Disorders: A Review of the Literature.骨髓增殖性疾病的心血管表现：文献综述
Hosp Physician. 1999 Jul;35(7):43-54.
2
Aging and hypertension decrease endothelial NO-related dilating function and gamma-glutamyl transferase activity but not S-nitrosoglutathione-induced aortic vasodilation.衰老和高血压会降低内皮一氧化氮相关的舒张功能以及γ-谷氨酰转移酶活性，但不会降低S-亚硝基谷胱甘肽诱导的主动脉血管舒张。
Fundam Clin Pharmacol. 2018 Apr;32(2):134-140. doi: 10.1111/fcp.12347. Epub 2018 Feb 1.
3
L-arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia.L-精氨酸是预防内皮功能障碍的有效药物，内皮功能障碍是急性白血病患者蒽环类药物心脏毒性的一个预测指标。
Exp Oncol. 2017 Dec;39(4):308-311.
4
The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels.衰老的心血管系统：从细胞和临床层面理解它。
J Am Coll Cardiol. 2017 Apr 18;69(15):1952-1967. doi: 10.1016/j.jacc.2017.01.064.
5
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.真性红细胞增多症和原发性血小板增多症：2017 年诊断、危险分层和治疗更新。
Am J Hematol. 2017 Jan;92(1):94-108. doi: 10.1002/ajh.24607.
6
Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera.原发性血小板增多症和真性红细胞增多症患者内皮及血小板状态的标志物
Hematology. 1999;4(5):397-402. doi: 10.1080/10245332.1999.11746464.
7
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
8
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.在当代真性红细胞增多症患者中，血栓形成率和风险因素描绘出一种新的临床流行病学特征。
Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610.
9
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.在世界卫生组织分类的原发性血小板增多症中，比较阿那格雷与羟基脲：ANAHYDRET 研究，一项随机对照试验。
Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.
10
Thrombotic disease in the myeloproliferative neoplasms.骨髓增殖性肿瘤中的血栓性疾病。
Hematology Am Soc Hematol Educ Program. 2012;2012:571-81. doi: 10.1182/asheducation-2012.1.571.

骨髓增殖性疾病中通过血流介导的血管舒张评估内皮功能障碍

Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.

作者信息

Yildiz Abdulkerim, Güryildirim Melike, Pepeler Mehmet Sezgin, Yazol Merve, Oktar Suna Özhan, Acar Kadir

机构信息

1 Faculty of Medicine, Department of Internal Medicine, Gazi University, Ankara, Turkey.

2 Faculty of Medicine, Department of Radiology, Gazi University, Ankara, Turkey.

出版信息

Clin Appl Thromb Hemost. 2018 Oct;24(7):1102-1108. doi: 10.1177/1076029618766260. Epub 2018 Apr 22.

DOI:10.1177/1076029618766260
PMID:29683036
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6714746/
Abstract

BACKGROUND

Thrombosis is the most important cardiovascular complication of classical myeloproliferative disorders (MPDs). Endothelial dysfunction (ED) is known to play a major role in the mechanism of thrombophilia in MPDs.

METHODS

Endothelial dysfunction and its associations with other parameters were investigated. A total of 18 patients with polycythemia vera (PV), 24 with essential thrombocytosis (ET), 7 with primary myelofibrosis (PMF), and 30 healthy patients as a control group were included in the study. To assess the ED, flow-mediated dilatation (FMD) measurements were used.

RESULTS

The FMD (%) result showing ED was determined as 9.9 (0.0-21.6) in the patients with PV, 7.3 (0.0-30.5) in patients with ET, 7.5 (0.0-18.0) in patients with PMF, and 13.9 (6.2-26.7) in the control group. The FMD (%) was markedly impaired in all patients with MPD compared to the control patients (7.8 [0.0-30.5] vs 13.9 [6.15-26.8], P = .02). According to the disease subtypes, FMD (%) was significantly lower in the ET group than in the control group ( P = .01).

CONCLUSION

Endothelial function was assessed in patients with MPD having FMD and was determined to demonstrate ED. Lower FMD was associated with older age, leukocytosis, thrombocytosis, and thrombosis history.

摘要

背景

血栓形成是经典骨髓增殖性疾病（MPD）最重要的心血管并发症。已知内皮功能障碍（ED）在MPD的血栓形成机制中起主要作用。

方法

研究内皮功能障碍及其与其他参数的关联。本研究纳入了18例真性红细胞增多症（PV）患者、24例原发性血小板增多症（ET）患者、7例原发性骨髓纤维化（PMF）患者以及30例健康患者作为对照组。采用血流介导的血管舒张（FMD）测量来评估内皮功能障碍。

结果

PV患者中显示内皮功能障碍的FMD（%）结果为9.9（0.0 - 21.6），ET患者为7.3（0.0 - 30.5），PMF患者为7.5（0.0 - 18.0），对照组为13.9（6.2 - 26.7）。与对照患者相比，所有MPD患者的FMD（%）均明显受损（7.8 [0.0 - 30.5] 对 13.9 [6.15 - 26.8]，P = 0.02）。根据疾病亚型，ET组的FMD（%）显著低于对照组（P = 0.01）。

结论

对采用FMD评估的MPD患者的内皮功能进行了评估，结果显示存在内皮功能障碍。较低的FMD与年龄较大、白细胞增多、血小板增多和有血栓形成病史相关。